Rick Panicucci
Chief Tech/Sci/R&D Officer at NRX PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-03-30
Profile
Riccardo Panicucci is currently an Independent Director at Q BioMed, Inc., a Director at MaveriX Oncology, Inc., an Independent Director at Cognos Therapeutics Holdings, Inc., the Senior Vice President-CMC at QED Therapeutics, Inc., the Senior Vice President at Calcilytix Therapeutics, Inc., and the Chief Technology Officer at NRX Pharmaceuticals, Inc. Previously, he worked as a Director-Foundation Development at Vertex Pharmaceuticals, Inc., the Vice President-Pharmaceutical Development at Wuxi Apptec, Inc., and the Senior Vice President at Origin Biosciences, Inc. He holds a doctorate degree from the University of Toronto and an undergraduate degree from McMaster University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-06 | 0 ( -.--% ) | - $ | 2024-03-30 |
Rick Panicucci active positions
| Companies | Position | Start |
|---|---|---|
| Q BIOMED INC. | Director/Board Member | 2018-02-12 |
| NRX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
MaveriX Oncology, Inc.
 MaveriX Oncology, Inc. BiotechnologyHealth Technology MaveriX Oncology, Inc. operates as a a biotechnology company. It focuses on the discovery, development, and commercialization of targeted small molecule cancer chemo-immunotherapies. The company was founded by Steven A. Everett and Craig Alan Coburn in 2015 and is headquartered in Palo Alto, CA. | Director/Board Member | - |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Corporate Officer/Principal | 2018-04-30 |
| Calcilytix Therapeutics, Inc. | Corporate Officer/Principal | - |
Former positions of Rick Panicucci
| Companies | Position | End |
|---|---|---|
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Corporate Officer/Principal | 2021-12-31 |
Wuxi Apptec, Inc.
 Wuxi Apptec, Inc. Data Processing ServicesTechnology Services Wuxi Apptec, Inc. provides pharmaceutical and biotechnology services. Its services include discovery, lab testing division, small molecule pharmaceutical development and manufacturing international discovery service unit, WuXi biologics, chemistry, bioanalytical, clinical & regulatory, genome center, biological reagents and WuXi venture fund. The company was founded by Ge Li in December 2000 and is headquartered in St. Paul, MN. | Corporate Officer/Principal | 2018-03-31 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Training of Rick Panicucci
| University of Toronto | Doctorate Degree |
| McMaster University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Q BIOMED INC. | Health Technology |
| NRX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Wuxi Apptec, Inc.
Wuxi Apptec, Inc. Data Processing ServicesTechnology Services Wuxi Apptec, Inc. provides pharmaceutical and biotechnology services. Its services include discovery, lab testing division, small molecule pharmaceutical development and manufacturing international discovery service unit, WuXi biologics, chemistry, bioanalytical, clinical & regulatory, genome center, biological reagents and WuXi venture fund. The company was founded by Ge Li in December 2000 and is headquartered in St. Paul, MN. | Technology Services |
MaveriX Oncology, Inc.
MaveriX Oncology, Inc. BiotechnologyHealth Technology MaveriX Oncology, Inc. operates as a a biotechnology company. It focuses on the discovery, development, and commercialization of targeted small molecule cancer chemo-immunotherapies. The company was founded by Steven A. Everett and Craig Alan Coburn in 2015 and is headquartered in Palo Alto, CA. | Health Technology |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Health Technology |
| Calcilytix Therapeutics, Inc. |
- Stock Market
- Insiders
- Rick Panicucci
